The evaluation of a positive direct antiglobulin test (autocontrol) in pretransfusion testing revisited.
Direct antiglobulin tests (DATs) using anti-IgG were performed on 65,049 blood samples from prospective transfusion recipients; 3570 tests (5.49%) were positive. Using criteria published previously (primarily excluding patients not transfused within the preceding 14 days), 778 samples from other than neonatal patients were selected for further evaluation. Eluates that did not react were obtained on 518 (66.6%) of these samples. Warm-reactive autoantibodies were apparent in 192 eluates, while 16 contained drug-related antibodies, anti-A or anti-B from prior transfusion with ABO mismatched blood components, or anti-D passively acquired from immune serum globulin. Fifty-two eluates contained alloantibodies; however, in only six of these cases did the corresponding serum lack unexpected alloantibodies, as determined by routine pretransfusion studies. Three additional weakly reactive clinically significant alloantibodies were detected solely through additional serum tests performed on DAT-positive samples. On the basis of these findings, the DAT had a low predictive value when used to detect the early manifestations of an immune response to recently transfused red cells. Elimination of the autocontrol from routine pretransfusion testing, therefore, carries minimal risk to patients yet will undoubtedly contribute to the containment of health care costs. Moreover, the risk is lower than that associated with the elimination of the antiglobulin crossmatch.
W J
WJ
Judd
B A
BA
Barnes
E A
EA
Steiner
H A
HA
Oberman
D B
DB
Averill
S H
SH
Butch
D000918:Antibody Specificity; D001788:Blood Grouping and Crossmatching / Q000379:methods*; D001803:Blood Transfusion / Q000379:methods*; D003298:Coombs Test / Q000379:methods*; D006801:Humans; D007231:Infant, Newborn; D007518:Isoantibodies / Q000032:analysis
D007518:Isoantibodies